Adaptive Biotechnologies (ADPT) Accounts Payables (2018 - 2026)

Adaptive Biotechnologies has reported Accounts Payables for 9 years, with the latest figure at $9.6 million in Q1 2026.

• Quarterly Accounts Payables rose 51.13% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (up 51.13% YoY) and the FY2025 annual result came in at $6.5 million, down 10.98% from the prior year.
• Accounts Payables climbed to $9.6 million in Q1 2026 per ADPT's latest filing, from $6.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $12.2 million in Q1 2024 and troughed at $2.7 million in Q2 2022.
• A 5-year average of $7.3 million and a median of $7.3 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables tumbled 55.36% in 2022, then jumped 236.88% in 2023.
• Over 5 years, Accounts Payables stood at $8.1 million in 2022, then fell by 4.52% to $7.7 million in 2023, then retreated by 5.88% to $7.3 million in 2024, then fell by 10.98% to $6.5 million in 2025, then jumped by 48.68% to $9.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $9.6 million, $6.5 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.